Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

• ClinicalTrials.gov Identifier: NCT01355484
• Recruitment Status: Completed
• First Posted: May 18, 2011
• Results First Posted: March 3, 2016
• Last Update Posted: March 3, 2016
• Sponsor: GTx
• Information provided by (Responsible Party): GTx

Tracking Information

• First Submitted Date: May 12, 2011
• First Posted Date: May 18, 2011
• Results First Submitted Date: February 4, 2016
• Results First Posted Date: March 3, 2016
• Last Update Posted Date: March 3, 2016
• Study Start Date: July 2011
• Actual Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 4, 2016)

• Physical Function [ Time Frame: Day 84 ]
  Measure is the percentage of subjects at day 84 with stair climb power change >=10% from their baseline value.
• Lean Body Mass [ Time Frame: Day 84 ]
  Measure is the percentage of subjects at day 84 with lean body mass change >=0% from their baseline value.

Original Primary Outcome Measures (submitted: May 17, 2011)

• Improved Physical function [ Time Frame: Day 84 ]
  Physical function will be assessed by stair climb power at Day 84. The percentage of change from baseline will be computed to determine if a subject is a physical function responder.
• Increased Lean body mass [ Time Frame: Day 84 ]
  At Day 84 a repeat Whole Body Composition Dexa Scan will be done and compared to the baseline Dexa.

• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
• Official Title: Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
• Brief Summary: The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
• Detailed Description: This is a randomized, double-blind, placebo controlled, multicenter, multinational efficacy and safety study in subjects with non small cell lung cancer (NSCLC). Subjects will be evenly randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary efficacy analysis will be based on total lean body mass and physical function.
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment

Condition

• Muscle Wasting
• Non Small Cell Lung Cancer

Intervention

• Drug: GTx-024
  subjects will be randomized to receive GTx-024 for the full duration of the trial.
• Drug: placebo
  subject will receive placebo for the duration of the trial

Study Arms

• Experimental: GTx-024
  subject will receive GTx-024 treatment for the duration of the trial
  Intervention: Drug: GTx-024
• Placebo Comparator: Placebo
  subject will receive placebo for the duration of the trial
  Intervention: Drug: placebo

• Publications *: Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. Review.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 18, 2015): 321
• Original Estimated Enrollment (submitted: May 17, 2011): 300
• Actual Study Completion Date: June 2014
• Actual Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• give voluntary, signed informed consent in accordance with institutional policies
• be non-obese as defined as body mass index (BMI)< or = to 32 and weight <300 pounds (<136kg)
• have been diagnosed with Stage III or IV NSCLC
• be prior to first line chemotherapy
• planned first line chemotherapy regimen is platinum plus paclitaxel only or platinum plus docetaxel only
• if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery
• life expectancy of >6 months
• ECOG score <or=1
• Serum creatinine <or=2.0 mg/dL
• MALES - age >or= 30 years
• FEMALES - age >or=30 years and clinically confirmed as postmenopausal.Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for >or=6 months but <12 months they must have a serum FSH concentration of >or=50 mIU/mL and an estradiol concentration of <or=25 pg/mL. Surgical menopause is defined as bilateral oophorectomy.
• MALES - subjects must agree to use a double barrier method of contraception during the study and for 3 months after study completion. This may include the following: condom + spermicide or condom + oral hormonal contraception
• MALES - have a serum PSA of <or=4.0 ng/mL or a negative prostate biopsy (no prostate cancer)within 6 months of evaluation

Exclusion Criteria:

• Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
• Have ALT/SGOT or AST/SGPT above 1.5 times the upper limit of normal (ULN) without evidence of liver metastases and above 5 times the ULN in subjects with evidence of liver metastases
• Have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above 2 mg/dL at baseline
• Have biologic agents or kinase inhibitors as part of their first line chemotherapy regimen including, but not limited to bevacizumab (Avastin), gefitinib (Nexavar) and erlotinib (Tarceva)
• Cardiovascular: uncontrolled hypertension, congestive heart failure or angina
• Pulmonary: Stage 4 chronic obstructive pulmonary disease (COPD)
• positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed > 10 years prior to enrollment and no evidence of active liver disease
• positive screen for anti-HCV (Hepatitis C Antibody),hepatitis A antibody IgM, or HIV
• currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds, including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)
• currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss
• have a baseline stair climb time >or=30 seconds (mean of two stair climbs)
• Have active cancer, other than NSCLC, or non-melanoma carcinoma of the skin, within the previous two years

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 30 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01355484
• Other Study ID Numbers: G300504; POWER1 ( Other Identifier: GTx )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: GTx
• Study Sponsor: GTx
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: GTx
• Verification Date: February 2016